Results 181 to 190 of about 19,943,678 (222)

Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis

American Journal of Medicine, 2017
Background Non-vitamin K oral anticoagulants are now proven alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation. However, there are few data on the efficacy and safety of their use for cardioversion, in which the risk of ...
Fabrizio Ricci, Giulia Renda, Raffaele De Caterina   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Reversal agents for non-vitamin K antagonist oral anticoagulants

Nature Reviews Cardiology, 2018
The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit coagulation factor Xa. Although clinical studies of NOACs were conducted without antidotes, patient outcomes with major bleeding when receiving NOACs were no worse than those in ...
Jerrold H, Levy, James, Douketis, Jeffrey I, Weitz   +2 more
openaire   +2 more sources

Pros and Cons of Vitamin K Antagonists and Non–Vitamin K Antagonist Oral Anticoagulants

Seminars in Thrombosis and Hemostasis, 2015
Anticoagulant treatment can be currently instituted with two different classes of drugs: the vitamin K antagonists (VKAs) and the newer, "novel" or non-vitamin K antagonist oral anticoagulant drugs (NOACs). The NOACs have several practical advantages over VKAs, such as the rapid onset/offset of action, the lower potential for food and drug interactions,
RIVA, NICOLETTA, AGENO, WALTER
openaire   +4 more sources

Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation

Hematology/Oncology Clinics of North America, 2016
For more than 50 years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved for prevention of thromboembolism in patients with nonvalvular AF.
Anna, Plitt, Christian T, Ruff, Robert P, Giugliano   +2 more
openaire   +2 more sources

Non-vitamin K antagonist oral anticoagulants and infective endocarditis

Heart, 2018
To the Editor  We read with great interest the Editorial by Erwin and Lung, which stated that in patients treated with oral anticoagulants and concomitant infective endocarditis, it is recommended to switch/bridge with heparin in the first 2 weeks to decrease the bleeding risk if cerebral embolism occurs, particularly in staphylococcal endocarditis.1 ...
Caldeira, Daniel, Ferreira, Joaquim J, Pinto, Fausto J., Costa, João   +3 more
openaire   +3 more sources

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel

Thrombosis and Haemostasis, 2014
Note: The editorial process for this paper was fully handled by Prof Christian Weber, Editor in Chief.
Husted, S, De Caterina, R, Andreotti, F, Arnesen, H, Bachmann, F, Huber, K, Jespersen, J, Kristensen, S D, Lip, G Y H, Morais, J, Rasmussen, Lars Hvilsted, Siegbahn, A, Storey, R F, Weitz, J I, Esc Working Group On Thrombosis Task Force On Anticoagulants In Heart Disease, On Behalf Of The   +14 more
openaire   +6 more sources

Comparison of non‐vitamin K antagonist oral anticoagulants on bleeding and thrombosis

Journal of Clinical Pharmacy and Therapeutics, 2021
Limited data are available for the comparison between different non-vitamin K antagonist oral anticoagulants (NOACs) on clinical outcomes. We aimed to provide evidence of different NOACs for patients with non-valvular atrial fibrillation (NVAF).Electronic databases were searched from inception through 22 March 2020 to identify eligible studies in which
Zhiyan Liu, Lingyue Ma, Hanxu Zhang, Guangyan Mu, Qiufen Xie, Shuang Zhou, Zining Wang, Zhe Wang, Kun Hu, Yanjun Gong, Jie Jiang, Qian Xiang, Yimin Cui   +12 more
openaire   +2 more sources

Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation

International Journal of Cardiology, 2016
PubMed ID ...
Özcan Başaran, Volkan Doğan, Cem Şahin, Murat Biteker   +3 more
openaire   +3 more sources

Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis

Journal of Thrombosis and Thrombolysis, 2018
Intracardiac thrombus most commonly develops in the left atrial appendage (LAA) and left ventricle (LV) in the setting of atrial fibrillation (AF) and post-myocardial fibrillation (MI), respectively. Current guidelines recommend that patients with post-MI LV or LAA thrombus should be treated with vitamin K antagonist (VKA).
Eiman Ghaffarpasand, Maneli D. Tehrani, Jolanta Marszalek, Gerald Chi   +3 more
openaire   +2 more sources

Misdosing of Non–Vitamin K Antagonist Oral Anticoagulants in Primary Care

Clinical Therapeutics, 2020
Prescription patterns of non-vitamin K antagonist oral anticoagulants (NOACs) are unknown among primary care physicians, where most patients with nonvalvular atrial fibrillation (NVAF) are diagnosed and followed up. The goal of this study was to evaluate overdosing and underdosing of NOACs in patients with NVAF followed up in primary care and determine
Carlos Seiça, Cardoso, João André, Sousa, Pedro, Simões, Beatriz, Silva, Ana, Albuquerque, Ana, Esperança, Ana, Cibrão, Artur, Correia, Joana, Gonçalves, Joana, Mortágua, José Eduardo, Almeida, Leonor, Oliveira, José, Garcia, Mariana, Duarte, Mariana, Loureiro, Marta, Costa E Silva, Marta, Fraga, Paulo, Lopes, Rui, Brandão, Susana, Miguel, Teresa, Queirós, Gustavo, Santo, Fernando, Silva, João, Sargento-Freitas   +23 more
openaire   +2 more sources